Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
about
Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Imaging of HCC-Current State of the ArtEvaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imagingPredictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Optimal combination of antiangiogenic therapy for hepatocellular carcinomaCirculating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlookNanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinomaTreatment of hepatocellular carcinoma: Steps forward but still a long way to goSystemic therapy of hepatocellular carcinoma: current status and future perspectivesNew approaches for precise response evaluation in hepatocellular carcinomaMolecular classification and novel targets in hepatocellular carcinoma: recent advancements¹⁸F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary studyShort-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.Multiparametric MR Imaging in Abdominal Malignancies.Normalization of the vasculature for treatment of cancer and other diseases.A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model--initial experience.Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathwayPhase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group studyPhase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceCD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE).Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells.Molecular mechanisms of resistance to tumour anti-angiogenic strategiesBiomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancerTumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical modelsA multidisciplinary approach to the management of hepatocellular carcinoma.Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaHepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens
P2860
Q26752752-671BFD9C-D49A-47E6-BF42-06747512C468Q26766689-784042B5-463C-40D5-8F24-27593C7252D0Q26768463-A368C695-8D10-4BB3-AEC1-5E6F9519EBC8Q26783895-8DE999B2-2AF8-436D-99E9-AB397302B220Q26784218-B14A5D0E-77C9-471F-BD8A-29E69B1F72A1Q26799458-4B08139E-02D3-40DC-B46E-60E5D2514807Q26823035-E84C2CE3-33BE-47DA-9A6B-FCF78D2F70F1Q26823523-300DA22A-EB18-4B08-9951-E9966224362CQ26865456-899B04D6-90A1-47C8-BD26-9CB39142C521Q26865844-E7E4ED02-F9D8-475F-B5B3-551BDC3CE0BDQ26866367-253EB51A-09A8-403C-B049-1471D3C7924AQ28383646-CCE0C093-DF6A-4EF6-9528-A0081E1B9C0BQ28687190-87C4EF62-F4BD-4E4B-8AFE-C206CCCA5F63Q30240170-870BF3D4-75CD-4918-A5B5-35DE66C7BFBFQ30364605-2C8429C0-A069-4A8A-A029-4AA6A281B602Q30471456-AF5DFA3B-81AA-4733-897C-82E6A060B398Q30493217-7EE832CD-B5D8-4693-9B40-EE1E174DA10BQ30542073-4F5AA059-4E8C-46EB-BDAA-DD1ECDCABA45Q30559275-680BCC53-64D0-4D32-BDA5-950D6ED0555BQ31030824-11FB7678-ACE6-4E8F-BE24-9069CA88154EQ31119452-72F94D43-856B-4B21-8007-18A7F98FF588Q33390267-7A23516E-91A5-49EB-9CF3-FA81BA9C3F10Q33391770-667E61D0-F2EE-4745-9CEE-D388D66F546BQ33395853-0C39F3A9-B87D-49B3-BCDF-59A643B4F289Q33413742-3D1F4F17-4CCD-4E7D-B321-184508882627Q33496309-B57A6940-47C8-4093-BA5F-4C8EB8CB06FBQ33559444-F6997FEF-37A8-4BA0-9A29-C93352606924Q33627739-65BA6A41-3FF1-41D1-98B3-54DC9BC59D7BQ33630819-22AFC9FD-1DFF-41A8-8AD8-3DC34F8BAFA1Q33686817-FF4F947E-9E1D-4E68-9B13-747464F2B49EQ33713444-08F243EE-2703-4988-BFF1-F0EF3E16B236Q33718025-BCA43603-D809-4BBA-8133-96BAD8011AE3Q33757046-7DE13B67-C74C-4137-B72A-7F94C4A2D9B6Q33808012-BC2FB16E-0DCE-4055-98E9-263453621768Q33811126-539B4B1A-9A97-4EAB-8900-D6EBDF800A4EQ33916361-B63C0FDF-3C56-468C-AA81-DB11A69D0E76Q33920350-748159A7-1373-4283-A421-C8B798257D20Q33990834-9D762F3E-F855-4E2C-996A-BB4DD01CBC51Q34131801-C3029B7A-4799-4ECD-9EED-964005432BD7Q34309960-995D8D28-F3AA-45FF-86A6-80E0005261C4
P2860
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Efficacy, safety, and potentia ...... r carcinoma: a phase II study.
@ast
Efficacy, safety, and potentia ...... r carcinoma: a phase II study.
@en
type
label
Efficacy, safety, and potentia ...... r carcinoma: a phase II study.
@ast
Efficacy, safety, and potentia ...... r carcinoma: a phase II study.
@en
prefLabel
Efficacy, safety, and potentia ...... r carcinoma: a phase II study.
@ast
Efficacy, safety, and potentia ...... r carcinoma: a phase II study.
@en
P2093
P2860
P50
P356
P1476
Efficacy, safety, and potentia ...... r carcinoma: a phase II study.
@en
P2093
Andrew X Zhu
Aram F Hezel
Dan G Duda
David P Ryan
Dushyant V Sahani
Emmanuelle di Tomaso
Eunice L Kwak
Jeffrey W Clark
Johanna Lahdenranta
Lawrence S Blaszkowsky
P2860
P304
P356
10.1200/JCO.2008.20.9908
P407
P577
2009-05-26T00:00:00Z